Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)

20260 citationsJournal Articlehybrid Open Access

Authors

Omar Abdel‐Rahman · University of Alberta

Paul Taylor · Wythenshawe Hospital

M. O’Brien · Royal Marsden NHS Foundation Trust

Jo Raskin · Antwerp University Hospital

Claudio Dazzi · Ospedale Santa Maria

Veerle Surmont · Universitair Ziekenhuis Brussel

S. Zonato ·

Abstract

Descriptive analyses suggest switch maintenance nintedanib does not improve PFS nor OS compared to placebo. Efficacy of the placebo arm may be related to imbalanced immunotherapy usage.

Topics & Keywords

Occupational and environmental lung diseases Myasthenia Gravis and Thymoma Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Lung Cancer

Volume 213, pp. 108906-108906

DOI: 10.1016/j.lungcan.2026.108906

Field-Weighted Citation Impact: 0.00